NOVO B NOVO NORDISK A/S

Vedtægter for Novo Nordisk A/S 2026

Vedtægter for Novo Nordisk A/S 2026

Vedtægter for Novo Nordisk A/S 2026

Vedhæftet fil



EN
27/03/2026

Underlying

NOVO BNOVO NORDISK A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NOVO NORDISK A/S

 PRESS RELEASE
Free
NOVO B NOVO NORDISK A/...

Vedtægter for Novo Nordisk A/S 2026

Vedtægter for Novo Nordisk A/S 2026 Vedtægter for Novo Nordisk A/S 2026 Vedhæftet fil

11h / 58m 1 EN
 PRESS RELEASE
Free
NOVO B NOVO NORDISK A/...

Articles of Association for Novo Nordisk A/S 2026

Articles of Association for Novo Nordisk A/S 2026 Articles of Association for Novo Nordisk A/S 2026 Attachment

11h / 58m 1 EN
 PRESS RELEASE
Free
NOVO B NOVO NORDISK A/...

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-...

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per weekNovo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026. Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awi...

22h / 44m 1 EN
 PRESS RELEASE
Free
NOVO B NOVO NORDISK A/...

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Resolutions from the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Lars Rebien Sørensen, chair of the Board of Directors, stated:“2025 was a year of profound transformation for Novo Nordisk and this extraordinary period has taught us some important lessons. We are reshaping our traditional approach to patient care and market access, and we need to meet patients where they are. The year ahead will test our determination and capabilities, and we face it with confidence, kno...

March 26, 2026 1 EN
 PRESS RELEASE
Free
NOVO B NOVO NORDISK A/...

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 23 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will repurc...

March 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch